Lipoprotein(a): Don’t forget about secondary prevention-Reference-Cited by-同舟云学术

Lipoprotein(a): Don’t forget about secondary prevention

Published:2024-08-21 Issue: Volume: Page:
ISSN:2047-4873
Container-title:European Journal of Preventive Cardiology
language:en
Short-container-title:

Author:

Bhatia Harpreet S¹,Boccara Franck²³^ORCID

Affiliation:

1. Division of Cardiovascular Medicine, University of California San Diego , La Jolla, CA , USA

2. Cardiology Department, CHU Saint-Antoine, APHP , Paris , France

3. GRC n°22, C2MV-Complications Cardiovasculaires et Métaboliques chez les patients vivant avec le Virus de l'immunodéficience humaine, Inserm UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Université , Paris , France

Funder

NIH

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwae276/59022248/zwae276.pdf

Reference14 articles.

1. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies;Bhatia;J Clin Med,2022

2. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention;Yoon;JACC Cardiovasc Interv,2021

3. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies;Qin;Atherosclerosis,2013

4. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population;Park;Clin Exp Pharmacol Physiol,2015

5. Lipoprotein (a) is related to in-stent neoatherosclerosis incidence rate and plaque vulnerability: optical coherence tomography study;Yuan;Int J Cardiovasc Imaging,2023